CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
CapsoVision (NASDAQ: CV) will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CapsoVision (NASDAQ: CV) will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after market close.
The company will host a conference call and live webcast on March 26, 2026 at 1:30 pm PT / 4:30 pm ET to discuss results and provide a corporate update. Dial-in numbers: (800) 715-9871 (US) or (646) 307-1963 (international); conference ID 2525025. The webcast replay will be available for one year via the Events page in investor relations; registration required to access the replay.
Details
News Market Reaction – CV
On Mar 13, the first trading day after this news, CV closed 2.99% above the previous close.
Data tracked by StockTitan Argus for the Mar 13 session.
Key Figures
- Earnings release date
- March 26, 2026
- Q4 and full-year 2025 financial results release after market close
- Conference call time
- 4:30 pm ET
- Scheduled start time for Q4/FY25 results call and corporate update
- Domestic dial-in
- (800) 715-9871
- US phone number to access the earnings conference call
- International dial-in
- (646) 307-1963
- International phone number to access the earnings conference call
- Conference ID
- 2525025
- ID required when dialing in to the earnings call
- Webcast availability
- 1 year
- Archived webcast access period following completion of the call
Historical Context
-
ROTH Conference participation with fireside chat and 1x1 investor meetings.
-
510(k) submission for AI-assisted reading module in CapsoCam Plus.
-
Benchmark investor conference participation with senior management meetings.
-
Q3 2025 financial results with revenue growth and operating expense increases.
-
Breakthrough Device Designation application for pancreatic cancer capsule.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Thursday, March 26, 2026, at 4:30 pm ET
SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conference ID 2525025, or from the webcast link on the Events page in the investor relations section of the company’s website.
To access the replay, please register via the webcast link on the Events page. The webcast will be available for one year following the completion of the call.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.